Literature DB >> 830420

Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil.

J R Bertino, W L Sawicki, C A Lindquist, V S Gupta.   

Abstract

The antitumor effects of methotrexate with 5-fluorouracil against the Sarcoma 180 mouse tumor model were found to be schedule dependent. Pretreatment of tumor-bearing animals with methotrexate significantly enhanced the antitumor activity of the combination relative to simultaneous treatment or to those with methotrexate following 5-fluorouracil. These studies indirectly support the hypothesis that methotrexate pretreatment with 5-fluorouracil is synergistic by increasing the amount of thymidylate synthetase bound to the active metabolite of 5-fluorouracil.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 830420

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  29 in total

1.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

Authors:  R G Moran; M Mulkins; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case.

Authors:  H Onodera; R Nishitai; K Shimizu; S Maetani; M Imamura
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 3.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.

Authors:  K Wayss; R Herrmann; J Mattern; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

5.  S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Authors:  Charles D Blanke; Kari Chansky; Kathy L Christman; Scott A Hundahl; Brian F Issell; Peter J Van Veldhuizen; G Thomas Budd; James L Abbruzzese; John S Macdonald
Journal:  Am J Clin Oncol       Date:  2010-04       Impact factor: 2.339

Review 6.  The fluoropyrimidines: biochemical mechanisms and design of clinical trials.

Authors:  M A Friedman; W Sadée
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.

Authors:  D J Fernandes; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.

Authors:  Hisashi Usuki; Ken Ishimura; Shinichi Yachida; Masanobu Hagiike; Keiichi Okano; Kunihiko Izuishi; Yukihiko Karasawa; Fuminori Goda; Hajime Maeta
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

10.  Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer.

Authors:  H Nakano; K Namatame; T Suzuki; H Takahashi; H Sakai; T Nakamura; K Kumada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.